KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Amortization of Deferred Charges (2016)

Historic Amortization of Deferred Charges for CRISPR Therapeutics AG (CRSP) over the last 1 years, with Q1 2016 value amounting to $8.0 million.

  • CRISPR Therapeutics AG's Amortization of Deferred Charges changed N/A to $8.0 million in Q1 2016 from the same period last year, while for Dec 2016 it was $8.0 million, marking a year-over-year change of. This contributed to the annual value of $8.0 million for FY2016, which is 819896.91% up from last year.
  • Latest data reveals that CRISPR Therapeutics AG reported Amortization of Deferred Charges of $8.0 million as of Q1 2016.
  • CRISPR Therapeutics AG's 5-year Amortization of Deferred Charges high stood at $8.0 million for Q1 2016, and its period low was $8.0 million during Q1 2016.